Effects of infliximab on apoptosis and reverse signaling of monocytes

Ringheanu, Mihaela; Markowitz, James; Chawla, Anupama; Daum, Fred; Lin, Xingyu; Silver, Jack

doi:10.1016/s0016-5085(03)80497-3

Cited by 4 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Neutralization of soluble TNF is clearly not enough as drugs like etanercept (p75 fusion protein) and onercept (p55 receptor) which bind TNF efficiently do not have clinical activity. This effect of infliximab is probably achieved by elimination of inflammatory cells expressing TNF‐ α on their membranes 17 mainly by induction of apoptosis of T cells and monocytes 18–21 . Recently, Shen et al .…”

Section: Introductionmentioning

confidence: 99%

Review article: infliximab therapy for inflammatory bowel disease – seven years on

Rutgeerts

Assche

Vermeire

2006

Aliment Pharmacol Ther

210

138

View full text Add to dashboard Cite

SUMMARYInfliximab, the chimeric monoclonal IgG1 antibody to tumour necrosis factor, is indicated for refractory luminal and fistulizing Crohn's disease and extra-intestinal manifestations of inflammatory bowel disease. Recently, the active ulcerative colitis trials (ACT) studies have shown that infliximab is also efficacious to treat ulcerative colitis resistant to standard therapy. Induction with 5 mg/kg infliximab at weeks 0, 2 and 6 is advocated.The response to infliximab is improved when concomitant immunosuppressive therapy is given. As the majority of patients will relapse if not retreated, a long-term strategy is necessary. Although episodic therapy can be used, the optimal strategy is systematic maintenance treatment with 5 mg/kg intravenous (i.v.) every 8 weeks. Long-term maintenance therapy with infliximab results in a reduction of the rate of complications, hospitalizations and surgeries associated with Crohn's disease.Safety problems with the monoclonal antibody infliximab treatment mainly concern the formation of antibodies to infliximab, which may lead to infusion reactions, loss of response and serum sickness-like delayed infusion reactions. Latent tuberculosis needs to be screened for. The rate of other opportunistic infections is slightly increased mainly in patients treated concomitantly with immunosuppression. There is no evidence that malignancy rates in patients treated with antitumour necrosis factor strategies are increased.

show abstract

Section: Introductionmentioning

confidence: 99%